De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Official title

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Study identification

NCT ID

NCT04852887

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

NRG Oncology

Other

Enrollment

1,670 participants

Conditions and interventions

Eligibility (public fields only)

Age range

50 Years to 70 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jun 22, 2021

Primary completion

Apr 7, 2031

Completion

Jun 30, 2041

Last update posted

Apr 22, 2026

2021 – 2041

United States locations

U.S. sites

812

U.S. states

49

U.S. cities

556

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.